One stop for everything needed. Once they begin to announce contracts with schools, businesses, etc it will run. It just makes sense to use the test to know what you need to be treated for and how you should be treated. The best of all worlds would be that they get another health agency to begin recommending the C-pass test before getting a booster.
New York, NY, and Tel Aviv, ISRAEL, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Quidel Lyra Influenza A & B and the Lyra RSV & hMPV PCR kits into production alongside COVID PCR tests currently being run (together the “Provista Respiratory Panel”) and expects this new respiratory panel to be launched in September 2021. The validation coincides with the recent validations for the cPass semi-quantitative COVID neutralizing antibody test and the Kogene COVID variant detection kits also being launched in September 2021. This positions Provista to now offer a turnkey solution for healthcare, businesses, school systems, government agencies, and others seeking access to a high-quality comprehensive lab to support testing programs as the US economy continues its reopening heading into the Fall of 2021.
CEO Gerald Commissiong will appear on the Yahoo! Finance Live Show at 4:10 pm EDT today, Wednesday September 1st, 2021 to discuss the recent developments at Provista as well as its plans to advance Tollovir, the Company’s oral, dual mechanism 3CL protease inhibitor/anti-cytokine antiviral drug candidate for COVID-19 treatment currently in a Phase 2 clinical trial
Find us at the office
Zawodniak- Bushar street no. 43, 41415 Nouakchott, Mauritania
Give us a ring
+77 583 658 542
Mon - Fri, 10:00-15:00